10 Best Low Priced Biotech Stocks to Buy Now

5. Cogent Biosciences, Inc. (NASDAQ:COGT)

Stock Price: $4.81

Number of Hedge Fund Holders: 38

Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. The company’s focus is on its clinical program, bezuclastinib, a selective tyrosine kinase inhibitor that potently inhibits the KIT D816V mutation and other mutations in KIT exon 17. The company ranks fifth on our list of the best low-priced biotech stocks to invest in now.

On May 6, Cogent Biosciences, Inc. (NASDAQ:COGT) released its Q1 2025 earnings, reporting $245.7 million in cash which is expected to support operations until late 2026. It also highlighted significant progress in its clinical trials. The SUMMIT trial reported promising results, with bezuclastinib undergoing a 65% mean improvement in Total Symptom Score for patients with non-advanced systemic mastocytosis.

Throughout 2025, Cogent Biosciences, Inc. (NASDAQ:COGT) plans to release top-line results from its SUMMIT, APEX, and PEAK trials. The commercial launch of bezuclastinib is also expected in 2026, reflecting the company’s focus on advancing its pipeline of genetically driven diseases with unmet medical needs.

In a report released on May 7, Louise Chen from Scotiabank maintained a Buy rating on Cogent Biosciences, Inc. (NASDAQ:COGT) and set a price target of $17.00.